GINS1 and diffuse large B-cell lymphoma: Our results confirm and extend previous reports linking FOXP1 overexpression to poor prognosis in DLBCL and may provide a potential FOXP1-GINS1 axis-based therapeutic strategy for reducing drug resistance in patients with DLBCL.